2m 2m 2m 2m 2m 2m 2m
Intellia Therape (NTLA)
NASDAQ
$15.42-$0.34 (-2.13%)
Price as of Jun 23, 2026 5:06 PM EDT- $2.2BMarket Cap
- 70.64%1-Year Change
- BiotechnologyIndustry
Intellia Therape (NTLA)
$15.42-$0.34 (-2.13%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 67.7M +16.92% | 57.9M +59.55% | 36.3M -30.40% | 52.1M +57.69% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 67.7M +16.92% | 57.9M +59.55% | 36.3M -30.40% | 52.1M +57.69% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -388.9M -16.61% | -466.3M +7.18% | -435.1M +3.59% | -420.0M +82.75% | |
Depreciation and Amortization Expense | 9.8M -5.04% | 10.3M +14.58% | 9.0M +18.54% | 7.6M +9.88% | |
Total Operating Expenses | 508.7M -14.10% | 592.1M +7.36% | 551.6M +8.09% | 510.3M +69.58% | |
Operating Profit | -441.0M -17.46% | -534.3M +3.68% | -515.3M +12.47% | -458.2M +71.05% | |
Interest Income | 29.2M -38.93% | 47.8M -4.06% | 49.8M +483.38% | 8.5M +565.78% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 29.2M -38.93% | 47.8M -4.06% | 49.8M +483.38% | 8.5M +565.78% | |
Total Nonoperating Income and Expense | 28.3M +85.64% | 15.2M -55.30% | 34.1M +312.83% | -16.0M -38,247.62% | |
Income before Taxes | -441.0M -17.46% | -534.3M +3.68% | -515.3M +12.47% | -458.2M +71.05% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -412.7M -20.49% | -519.0M +7.86% | -481.2M +1.48% | -474.2M +77.01% | |
Net Income from Continuing Operations Applicable to Common | -412.7M -20.49% | -519.0M +7.86% | -481.2M +1.48% | -474.2M +77.01% | |
Basic EPS and Net Income | -3.81 -27.43% | -5.25 -3.14% | -5.42 -12.01% | -6.16 +62.96% | |
Diluted EPS and Net Income | -3.81 -27.43% | -5.25 -3.14% | -5.42 -12.01% | -6.16 +62.96% | |
Basic Weighted Average Shares | 108.4M +9.64% | 98.8M +11.35% | 88.8M +15.33% | 77.0M +108,473.36% | |
Diluted Weighted Average Shares | 108.4M +9.64% | 98.8M +11.35% | 88.8M +15.33% | 77.0M +108,473.36% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 155.5M -17.82% | 189.2M -16.57% | 226.7M -56.69% | 523.5M +324.21% | |
Short-Term Investments | 294.4M -28.60% | 412.3M -39.85% | 685.5M +2.44% | 669.1M +7.01% | |
Cash and Cash Equivalents and Short-Term Investments | 449.9M -25.21% | 601.5M -34.06% | 912.2M -23.51% | 1.2B +59.29% | |
Total Current Assets | 527.7M -17.53% | 639.9M -35.91% | 998.3M -17.95% | 1.2B +58.17% | |
Accumulated Depreciation | 58.6M +17.94% | 49.7M +24.66% | 39.9M +20.07% | 33.2M +27.13% | |
Property and Plant and Equipment and Net | 17.7M -35.46% | 27.4M -16.42% | 32.8M +17.33% | 27.9M +33.16% | |
Total Long-Term Assets | 172.9M -39.87% | 287.6M +116.85% | 132.6M +36.36% | 97.3M -72.86% | |
Total Assets | 842.1M -29.29% | 1.2B -8.45% | 1.3B -14.42% | 1.5B +17.43% | |
Income Taxes Payable | 800,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 1.6M +700.00% | |
Total Current Liabilities | 103.9M -6.29% | 110.9M -3.78% | 115.2M -8.97% | 126.6M +0.57% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 66.8M -67.89% | 208.2M +53.55% | 135.6M +1.23% | 133.9M +4.33% | |
Total Liabilities | 170.7M -46.49% | 319.1M +27.21% | 250.8M +4.25% | 240.6M +26.12% | |
Retained Earnings | -2.6B +18.95% | -2.2B +31.30% | -1.7B +40.88% | -1.2B +67.45% | |
Total Stockholders Equity | 671.4M -23.00% | 872.0M -16.97% | 1.1B -15.01% | 1.2B +18.78% | |
Total Shares Outstanding | 116.3M +14.00% | 102.0M +9.71% | 93.0M +6.77% | 87.1M +16.94% | |
Cash Flow | |||||
Cash from Operating Activities | -394.7M +13.14% | -348.9M -11.47% | -394.1M +18.24% | -333.3M +48.11% | |
Capital Expenditures | 1.1M -80.46% | 5.8M -58.68% | 14.0M +3.15% | 13.6M +6.29% | |
Cash from Investing Activities | 228.0M +81.60% | 125.6M +500.57% | -31.3M -119.55% | 160.3M +129.11% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 131.5M -29.21% | 185.7M +42.53% | 130.3M -77.64% | 583.0M -20.87% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -651.67% -29.40% | -923.10% -35.02% | -1,420.51% +61.60% | -879.04% +8.47% | |
Return on Assets | -40.60% -2.54% | -41.66% +22.11% | -34.11% +1.24% | -33.69% +23.94% | |
Return on Equity | -53.48% -0.97% | -54.00% +28.27% | -42.10% +1.04% | -41.67% +21.90% | |
Revenue Growth | 16.92% -71.58% | 59.55% +295.88% | -30.40% -152.70% | 57.69% +234.14% | |
Current Ratio | 5.08 -12.00% | 5.77 -33.39% | 8.67 -9.87% | 9.61 +57.27% | |
Cash Ratio | 1.50 -12.31% | 1.71 -13.29% | 1.97 -52.42% | 4.14 +321.80% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow